Suit accuses Telix of breaching licence agreement for cancer drug Zircaix

Intellectual Property 2025-11-24 11:20 pm By Andy Sidler

Please login to bookmark

German pharmaceutical company Heidelberg Pharma has filed a lawsuit against Australian drug maker Telix alleging breach of a licence agreement for its kidney cancer diagnostic drug Zircaix.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au